Cargando…

Hormone naïve prostate cancer: predicting and maximizing response intervals

Hormone naïve advanced prostate cancer is subdivided into two disease states: biochemical recurrence and traditional M1 (metastatic) prostate cancer and characterized by no prior hormonal therapy or androgen deprivation therapy (ADT). In biochemical recurrence/prostate-specific antigen (PSA) recurre...

Descripción completa

Detalles Bibliográficos
Autor principal:	Moul, Judd W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Invited Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814946/ https://www.ncbi.nlm.nih.gov/pubmed/26112479 http://dx.doi.org/10.4103/1008-682X.152821

Ejemplares similares

The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK
por: Rosario, Derek J., et al.
Publicado: (2016)

Steroid hormone receptors and prostate cancer: role of structural dynamics in therapeutic targeting
por: Kumar, Raj
Publicado: (2016)

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer
por: Recine, Federica, et al.
Publicado: (2015)

Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
por: Maughan, Benjamin L, et al.
Publicado: (2014)

The maximal metabolic steady state: redefining the ‘gold standard’
por: Jones, Andrew M., et al.
Publicado: (2019)

African American Men With Low-Risk Prostate Cancer Are Candidates for Active Surveillance: The Will-Rogers Effect?
por: Qi, Robert, et al.
Publicado: (2017)

Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
por: Pham, Thy, et al.
Publicado: (2016)

Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014)

Prostate cancer stem cells
por: Lang, SH, et al.
Publicado: (2009)

Role of chemotherapy in prostate cancer
por: Nader, Rita, et al.
Publicado: (2018)

Vitamin D in prostate cancer
por: Trump, Donald L, et al.
Publicado: (2018)

Risk-prediction tools in prostate cancer: the challenge of tailoring
por: Morlacco, Alessandro, et al.
Publicado: (2016)

Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED
por: Aragon-Ching, Jeanny B
Publicado: (2016)

Glucocorticoids and prostate cancer treatment: friend or foe?
por: Montgomery, Bruce, et al.
Publicado: (2014)

The role of mRNA splicing in prostate cancer
por: Lapuk, Anna V, et al.
Publicado: (2014)

Current early diagnostic biomarkers of prostate cancer
por: Qu, Min, et al.
Publicado: (2014)

Clinical variability and molecular heterogeneity in prostate cancer
por: Shoag, Jonathan, et al.
Publicado: (2016)

Prostate cancer epigenetics and its clinical implications
por: Yegnasubramanian, Srinivasan
Publicado: (2016)

Perspectives on the clinical development of immunotherapy in prostate cancer
por: Cordes, Lisa M, et al.
Publicado: (2018)

Circulating tumor cells and their role in prostate cancer
por: Maas, Moritz, et al.
Publicado: (2019)

Maximizing virtual meetings and conferences: a review of best practices
por: Rubinger, Luc, et al.
Publicado: (2020)

Multiple therapeutic and preventive effects of 3,3′-diindolylmethane on cancers including prostate cancer and high grade prostatic intraepithelial neoplasia
por: Zhang, William Weiben, et al.
Publicado: (2014)

Prostate-associated gene 4 (PAGE4), an intrinsically disordered cancer/testis antigen, is a novel therapeutic target for prostate cancer
por: Kulkarni, Prakash, et al.
Publicado: (2016)

Cancer-cell-intrinsic mechanisms shaping the immunosuppressive landscape of prostate cancer
por: Zhu, Yini, et al.
Publicado: (2022)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Anti-angiogenesis in prostate cancer: knocked down but not out
por: Bilusic, Marijo, et al.
Publicado: (2014)

New developments in the treatment of castration resistant prostate cancer
por: Wadia, Roxanne, et al.
Publicado: (2014)

Genomic predictors for treatment of late stage prostate cancer
por: Shevrin, Daniel H
Publicado: (2016)

Lineage plasticity-mediated therapy resistance in prostate cancer
por: Blee, Alexandra M, et al.
Publicado: (2019)

Epigenetic regulation of prostate cancer: the theories and the clinical implications
por: Liao, Yiji, et al.
Publicado: (2019)

The role of glutamine metabolism in castration-resistant prostate cancer
por: Zhao, Bing, et al.
Publicado: (2023)

Genetic disorders of thyroid development, hormone biosynthesis and signalling
por: Moran, Carla, et al.
Publicado: (2022)

Metabolic Alterations, Aggressive Hormone-Naïve Prostate Cancer and Cardiovascular Disease: A Complex Relationship
por: Di Francesco, Simona, et al.
Publicado: (2019)

Multiparametric ultrasound in the detection of prostate cancer: a systematic review
por: Postema, Arnoud, et al.
Publicado: (2015)

Chemotherapy and its evolving role in the management of advanced prostate cancer
por: Schweizer, Michael T, et al.
Publicado: (2014)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

Clinical validity and utility of genetic risk scores in prostate cancer
por: Helfand, Brian T, et al.
Publicado: (2016)

Long noncoding RNAs in prostate cancer: overview and clinical implications
por: Malik, Bhavna, et al.
Publicado: (2016)

Molecular signaling involving intrinsically disordered proteins in prostate cancer
por: Russo, Anna, et al.
Publicado: (2016)

Phenotypic plasticity in prostate cancer: role of intrinsically disordered proteins
por: Mooney, Steven M, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_81tsmhf7j37nopit6lubev1kfv